For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Most deaths from cancer are explained by metastasis, and yet large-scale metastasis
research has been impractical owing to the complexity of in vivo models. Here we introduce …

Although several artificial nanotherapeutics have been approved for practical treatment of
metastatic breast cancer, their inefficient therapeutic outcomes, serious adverse effects, and …

A hallmark of metastasis is the adaptation of tumor cells to new environments. Metabolic
constraints imposed by the serine and glycine–limited brain environment restrict metastatic …

Primary tumors are known to constantly shed a large number of cancer cells into systemic
dissemination, yet only a tiny fraction of these cells is capable of forming overt metastases …

Background Astrocytes are crucial regulators in the central nervous system. Abnormal
activation of astrocytes contributes to some behavior deficits. However, mechanisms …

While hypoxia promotes carcinogenesis, tumour aggressiveness, metastasis, and resistance
to oncological treatments, the impacts of hyperoxia on tumours are rarely explored because …

Blood–brain/blood–tumor barriers (BBB and BTB) and interstitial transport may constitute
major obstacles to the transport of therapeutics in brain tumors. In this study, we examined …

This comprehensive review provides information on epidemiology, size, grade, cerebral
localization, clinical symptoms, treatments, and factors associated with longer survival in …